First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors

EP4, a prostaglandin E(2) receptor, has shown an immunosuppressive activity on cancer cells. This first‐in‐human study evaluated ONO‐4578, a highly selective EP4 antagonist, as monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors. A daily dose ranging fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasa, Satoru, Koyama, Takafumi, Nishino, Makoto, Kondo, Shunsuke, Sudo, Kazuki, Yonemori, Kan, Yoshida, Tatsuya, Tamura, Kenji, Shimizu, Toshio, Fujiwara, Yutaka, Kitano, Shigehisa, Shimomura, Akihiko, Sato, Jun, Yokoyama, Fumiharu, Iida, Hiroyuki, Kondo, Maki, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807514/
https://www.ncbi.nlm.nih.gov/pubmed/36082616
http://dx.doi.org/10.1111/cas.15574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807514/
https://www.ncbi.nlm.nih.gov/pubmed/36082616
http://dx.doi.org/10.1111/cas.15574

Ejemplares similares